Click here to download a PDF copy of the GOG Partners Connection Newsletter.

The post GOG Partners Connection Quarterly Newsletter – December 2025 appeared first on GOG.

PRESS RELEASE

For Immediate Release

Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart Mipitecan (LY4170156), a Novel ADC Targeting Folate Receptor Alpha (FRα), in Recurrent Ovarian Cancer

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3133, a pivotal Phase 3 clinical trial titled FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. The study is sponsored by Eli Lilly and Company and conducted in collaboration with The GOG Foundation, Inc.

Click here to read full press release.

The post GOG-3133/ FRAmework-01/ ENGOT-ov97/ <br>GINECO-NOGGO Press Release</br> appeared first on GOG.

Click here to download a PDF copy of the GOG Partners Connection Newsletter.

The post GOG Partners Connection Quarterly Newsletter – September 2025 appeared first on GOG.

PUBLICATION

The post The GOG Foundation and EVA/LACOG Partnership: A Collaborative Strategic Alliance for Clinical Trial Execution Publication appeared first on GOG.

PUBLICATION

Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: The GOG Foundation, Inc’s Scholar Career Development Award and New Investigator Program

HIGHLIGHTS

Click here to read the full publication.

The post IJGC GOG Foundation Scholar Career Development Award and New Investigator Program Publication appeared first on GOG.

PRESS RELEASE

For Immediate Release

FDA Approves the AVMAPKI FAKZYNJA Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

BOSTON–(BUSINESS WIRE)–May 8, 2025— Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK is the first and only FDA-approved medicine for this disease. This indication is approved under accelerated approval based on the tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. AVMAPKI plus FAKZYNJA is only commercially available in the U.S. as an oral combination co-pack with the two prescription products, known as “AVMAPKI FAKZYNJA CO-PACK.”

“Today’s approval of AVMAPKI FAKZYNJA CO-PACK for patients with KRAS-mutated recurrent low-grade serous ovarian cancer represents not only the first-ever FDA-approved treatment specifically for this rare cancer but also a new day for people living with this disease who have been in desperate need of new treatment options,” said Dan Paterson, president and chief executive officer of Verastem Oncology. “We are very proud to bring two innovative medicines in one combination treatment to the LGSOC community. We thank the researchers, patients, and their families participating in our clinical trials, the patient advocacy community, the FDA, and everyone at Verastem for their dedication and commitment to helping us bring AVMAPKI FAKZYNJA CO-PACK to patients in the U.S.”

The accelerated approval of AVMAPKI FAKZYNJA CO-PACK is based on the Phase 2 RAMP 201 clinical trial, which evaluated the combination of AVMAPKI and FAKZYNJA in adult patients with measurable KRAS-mutated recurrent LGSOC.

Click here to read full press release.

The post ENGOT-ov60 | GOG-3052 | RMAP 201<br>Verastem Onoclogy Press Release</br> appeared first on GOG.

Click here to download a PDF copy of the GOG Partners Connection Newsletter.

The post GOG Partners Connection Quarterly Newsletter – March 2025 appeared first on GOG.

PRESS RELEASE

For Immediate Release

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Mar. 31, 2025– Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review (PFS-BICR).

In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in risk of disease progression compared to patients treated with nab-paclitaxel alone (hazard ratio: 0.70; p-value: 0.008). Their median PFS-BICR was 6.5 months, compared to 5.5 months in patients who received nab-paclitaxel alone. At an interim evaluation of overall survival (OS), patients treated with relacorilant plus nab-paclitaxel had a significant improvement in OS, with a median OS of 16.0 months, compared to 11.5 months for patients receiving nab-paclitaxel alone (hazard ratio: 0.69; p-value: 0.012). Relacorilant was well-tolerated and no new safety signals were observed. As was the case in the company’s Phase 2 trial, safety and tolerability were comparable in the two groups.

Complete results from ROSELLA will be presented at a medical conference this year. Results from Corcept’s Phase 2 trial of relacorilant in patients with platinum-resistant ovarian cancer were published in the Journal of Clinical Oncology in June 2023.

Click here to view the press release.

The post ROSELLA GOG-3073 | ENGOT-OV72 <br>Corcept Therapeutics Incorporated Press Release</br> appeared first on GOG.